Emergo Therapeutics, Inc. Report issue

For profit Phase 2
Founded: Durham NC United States (2017)

Organization Overview

First Clinical Trial
2018
NCT03712163
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Emergo Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

norketotifen (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 2)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1